Correction to: Leukemia advance online publication 18 November 2016; doi:10.1038/leu.2016.300
Following the online publication of this article, the authors noted that Dr McMullin was incorrectly excluded from the author list. The complete author names are given above. Dr McMullin’s affiliation is Department of Haematology, Queen’s University, Belfast, UK.
Author information
Consortia
Additional information
The online version of the original article can be found at 10.1038/leu.2016.300
Rights and permissions
About this article
Cite this article
Tefferi, A., Al-Ali, H., Barosi, G. et al. Erratum: A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia 31, 1252 (2017). https://doi.org/10.1038/leu.2017.2
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.2
This article is cited by
-
How I manage anemia related to myelofibrosis and its treatment regimens
Annals of Hematology (2023)
-
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors
Current Hematologic Malignancy Reports (2022)
-
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
Leukemia (2021)
-
Rethinking clinical trial endpoints in myelodysplastic syndromes
Leukemia (2019)
-
Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis
Current Hematologic Malignancy Reports (2018)
